Ipamorelin

What Ipamorelin does

Ipamorelin prompts growth hormone release. Human research includes short IV studies and bowel-surgery trials. The published surgery trial did not show a significant benefit. Repeated injections under the skin for muscle, sleep or fat loss lack controlled outcome data. Blood sugar changes and product quality are key concerns.

• In a small study, an IV dose of ipamorelin caused a brief rise in growth hormone. (Studied in a trial)
• People report using it for muscle, fat loss and recovery, but controlled trials of these goals were not found. (Reported by users)
• People report bedtime use for sleep, though some reports describe anxiety and insomnia instead. (Reported by users)

Uses in the sources

• Studied after bowel resection to help bowel recovery; the published trial found no significant benefit. (Studied in a trial) (source)
• People report use for muscle, fat loss and recovery. Controlled trials of these home-use outcomes were not found. (Reported by users) (source)
• People use bedtime injections for sleep; reports also describe anxiety and insomnia. (Reported by users) (source)

Ipamorelin dosage

Typical reported dose: 100–200 mcg at bedtime, often with CJC no DAC

• IV PK: about 3 mcg/kg: 4.21 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV PK: about 10 mcg/kg: 14.02 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV PK: about 30 mcg/kg: 42.13 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV PK: about 60 mcg/kg: 84.27 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV PK: about 100 mcg/kg: 140.45 nmol/kg IV over 15 minutes; no titration. once in a single-dose cohort, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• Bowel surgery: IV twice daily: 0.03 mg/kg IV twice daily on postoperative days 1-7, or until discharge. twice daily, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Ipamorelin

Comes as: Lyophilized powder vial reported online, Trial-controlled IV infusion, Nasal spray reported in analytical studies and adverse reports.

Mixed with: Community reports use bacteriostatic water; this does not establish compatibility or sterility..

Common vial sizes: 5 mg. Common water amounts: 2 mL.

• 5 mg with 2 mL is one community report, not a label instruction.
• Syringe units mark volume, not peptide potency. Do not confuse mcg with mg.
• Bacteriostatic water does not sterilize contaminated powder or prove a stored mixture remains sterile.

Before mixing: Community storage varies; no validated shelf life for unregulated ipamorelin vials was found.

After mixing: Users report refrigeration. No validated multiweek stability or sterility period was found.

Ipamorelin side effects and risks

Reported side effects

• High blood sugar: 14.3% with ipamorelin versus 8.6% placebo at discharge., moderate (source)
• Low potassium: 12.5% versus 3.4% in postoperative patients., moderate (source)
• Insomnia: 10.7% versus 5.2% in the bowel surgery trial., mild (source)
• Serious postoperative events: 17.9% versus 15.5%; two active arm deaths. Surgery and illness confound cause., serious (source)
• Nausea, vomiting and bloating: unknown, moderate (source)
• Immune or allergic reaction: unknown, serious (source)

Stop and get help if

• Trouble breathing, tongue swelling, fainting or widespread hives: Stop and get emergency care now.
• Sudden severe headache, new vision loss or repeated vomiting: Get emergency assessment now; a pituitary or pressure problem must be excluded.
• Chest pain, severe breathlessness or collapse: Call emergency services now.
• Persistent severe abdominal pain or repeated vomiting: Stop and get urgent medical assessment.
• Confusion, seizure, or low blood sugar that does not resolve: Get emergency help now; do not drive.
• Fever with a hot, spreading, painful injection site: Get urgent care for a possible injection infection.

Who should avoid it

• pregnant: Avoid during pregnancy. Reproductive safety is unstudied; this screen is precautionary.
• breastfeeding: Avoid while breastfeeding. Human infant exposure and safety are unknown.
• tryingToConceive: Avoid while trying to conceive. Human fertility and early-pregnancy safety are unknown.
• under18: Historical child studies do not support unsupervised use in minors.
• activeCancer: GH and IGF-1 are growth signals. Avoid with active cancer; this applies GH-treatment precautions to secretagogues.
• cancerHistory: Prior cancer needs a clinician review before raising GH or IGF-1. Recurrence risk with this compound is unknown.
• diabetes: GH-related changes can worsen insulin sensitivity. Review blood sugar control and medicines.
• heartCondition: Fluid retention may strain the heart. Heart-disease safety is not established for home-use schedules.
• uncontrolledBloodPressure: Review uncontrolled blood pressure before use. Fluid retention and pressure changes need assessment.
• kidneyDisease: Kidney-disease dose adjustments and repeated-dose safety are not established.
• liverDisease: Liver-disease dose adjustments and repeated-dose safety are not established.
• diabeticRetinopathy: Review proliferative eye disease before raising GH or IGF-1. This is a GH-class precaution.
• pancreatitisHistory: Review prior pancreatitis. GH-class safety concerns do not establish a risk rate for this compound.
• sleepApnea: Review sleep apnea and new swelling. GH-related tissue or fluid changes are a class concern.
• surgeryPlanned: Tell the surgical team about use and all stacks. Perioperative safety depends on the specific study setting.
• testedAthlete: WADA bans this compound at all times, including out of competition.
• other: Do not add a GH secretagogue when GH or IGF-1 is already excessive. Investigate the cause.
• other: A pituitary mass needs specialist review. GH testing and GH-raising drugs are not interchangeable.

Interactions

• Insulin and sulfonylureas: GH-class precaution: insulin sensitivity and medicine needs can change. Exact interaction trials for this peptide are lacking.
• Other GH secretagogues, GH, and IGF-1: Overlapping GH/IGF-1 effects can add hormone, swelling and blood sugar risks. Combination benefit is not established.
• Glucocorticoids and oral estrogen: These can change GH responses or IGF-1 interpretation. Do not change prescribed hormone replacement to alter a peptide response.
• Anticoagulants and antiplatelets: General injection precaution: blood thinners increase bleeding/bruising risk. A direct interaction with this peptide has not been established.

Product quality risks

• Unregulated products may have the wrong identity, dose or sterility. A purity percentage alone cannot establish injection safety.
• Studies identified glycine-modified GHRP-2, GHRP-6 and ipamorelin in black-market or seized preparations.
• No representative market-wide contamination or underdosing rate was found for this compound.

What to expect

A bowel-surgery trial used IV infusions twice daily for up to seven days or until discharge; this does not define a home-injection course.

Five human research records, two from registries only, plus two reports to FDA. The published bowel-surgery trial found no clear benefit; a review includes the same trial.

Key studies

• First human IV dose study: IV ipamorelin produced a brief GH pulse; it did not test a chronic wellness regimen. (source)
• Bowel surgery: 0.03 mg/kg: The main and secondary efficacy analyses did not show a significant benefit. (source)
• Second bowel-surgery trial: A larger completed dose-finding trial remains a major unpublished-results gap. (source)
• Nasal exposure for doping analysis: This documents human nasal exposure, not a clinical-use schedule. (source)
• Veterans: mixed-treatment cohort: A registered mixed-treatment cohort provides no isolated ipamorelin outcome evidence. (source)
• Nasal headache report: Headache and watery eyes; product quality was questioned. (source)

Ipamorelin FAQ

• Is Ipamorelin FDA-approved? No FDA-approved product or dose label found; no approval for physique or performance use.
• How do people take it? Under the skin, once nightly. Guide reports 8-12 weeks on, then 4 weeks off.. Source: reported by users, not an established dose.
• What's the difference between Ipamorelin and Tesamorelin? Ipamorelin: an experimental peptide that triggers growth hormone release. Tesamorelin: a peptide approved for deep abdominal fat in adults with HIV lipodystrophy. Why people pair them: users add it for fat-loss goals; no direct combination trial was found.
• Can I take it with Tesamorelin? Users add it for fat-loss goals; no direct combination trial was found. No trial established the long-term safety or body-composition benefit of this combination. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Named on the 2026 list; prohibited in and out of competition.
• How long does a mixed vial last? Users report refrigeration. No validated multiweek stability or sterility period was found.